Regulatory Divergence in PSMA Targeted Therapy:...

By HEOR Staff Writer

April 27, 2026

Novartis withdrew its European Medicines Agency (EMA) application to expand the indication for Pluvicto® (lutetium (177Lu) vipivotide tetraxetan). The company sought to include adult patients with PSMA-positive metastatic castration-resistant pros...
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediat...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Advancing Multicenter AKI Prediction: Benefits of Collaborative Models Over L...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and ...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies
Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovas...
Zanidatamab Biliary Cancer Therapy: Advancing Targeted Treatment for HER2-Pos...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically ...
Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roa...
Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
Effective Hypertension Control Interventions in Underserved Populations